Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,321 papers from all fields of science
Search
Sign In
Create Free Account
Nelipepimut-S Plus GM-CSF Vaccine
Known as:
NeuVax Plus GM-CSF
, Nelipepimut-S Plus Sargramostim
, HLA A2/A3-Restricted HER-2/neu Peptide Vaccine Plus GM-CSF
Expand
A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Antigen Sensitization
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data
P. Dillon
,
C. Brenin
,
C. Slingluff
Breast Cancer
2020
Corpus ID: 215798777
Abstract Vaccine therapies for treatment and prevention of cancer have seen modest degrees of efficacy with wide variation…
Expand
2017
2017
Abstract OT3-01-04: VADIS trial: Phase II trial of the nelipepimut-S peptide vaccine in women with DCIS of the breast
E. Mittendorf
,
G. Plitas
,
+6 authors
P. Brown
2017
Corpus ID: 56857311
Background: Our group has been investigating vaccination strategies in breast cancer. Specifically, we have been evaluating HER2…
Expand
2016
2016
Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX…
H. Joensuu
,
P. Kellokumpu-Lehtinen
,
+13 authors
H. Lindman
2016
Corpus ID: 56817490
1001Background: The role of capecitabine (X) in the adjuvant treatment of BC is not established, and few long-term survival data…
Expand
2016
2016
A therapeutic Her 2 / neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her 2 / neu-expressing tumor in HLA-A 2 transgenic mice
T. Tran
,
M. Diniz
,
+10 authors
E. Tartour
2016
Corpus ID: 26850351
2016
2016
Effect of novel peptide vaccines on secondary recurrences and survivorship.
L. Chance
,
P. T. Gompper
,
G. Choy
Journal of Clinical Oncology
2016
Corpus ID: 23821930
e274 Background: According to the NCI Office of Cancer Survivorship, in 2014, it is estimated there are 14.5 million cancer…
Expand
2015
2015
Abstract OT3-1-09: Combination immunotherapy with trastuzumab and the HER2 vaccine E75 (nelipepimut-S) in high-risk HER2+ breast cancer patients to prevent recurrence
Beth A Mittendorf
,
E. Schneble
,
+7 authors
G. Peoples
2015
Corpus ID: 70859038
Background: In an adjuvant phase II trial, the HER2-derived nelipepimut-S (E75) + GM-CSF vaccine (Neuvax) has been shown to…
Expand
2015
2015
Abstract 2504: A therapeutic Her2-Neu cancer vaccine alone or in combination with anti-Her2 mAb inhibits tumor growth in HLA-A2 transgenic mice
T. Tran
,
M. Diniz
,
+5 authors
E. Tartour
2015
Corpus ID: 79009332
Her2/neu is a validated target in cancer, as various antibodies (Abs) against this antigen have demonstrated their clinical…
Expand
2014
2014
Breast cancer: E75—a safe and effective vaccine for the prevention of disease recurrence
A. Errico
Nature Reviews Clinical Oncology
2014
Corpus ID: 41626884
Breast cancer is the most common malignancy in women and even after curative treatment, approximately 10–20% of breast cancer…
Expand
2013
2013
Biomarker correlation to clinical response in phase I/II trials of the adjuvant breast cancer vaccine neuvax (nelipepimut-S or E75).
J. Berry
,
A. Trappey
,
+9 authors
D. C. V. Echo
2013
Corpus ID: 79055562
TPS3126 Background: We completed phase I/II clinical trials with NeuVax (nelipepimut-S), a HLA-A2/A3-restricted, HER2-derived…
Expand
2013
2013
Quantifying the timescales of fluid-rock interaction on Mars using the nakhlite meteorites
T. Tomkinson
,
Martin R. Lee
,
D. Mark
,
F. Stuart
,
Caroline L. Smith
2013
Corpus ID: 51732348
Etch pits within olivine grains from the nakhlite meteorites reveal the magnitude and timescale of water-mediated alteration of…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE